8-K filing — Lipocine Inc. (LPCN)
Filed: 2026-11-10 AccNo: 0001493152-26-050842 Size: 239 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-10 AccNo: 0001493152-26-050842 Size: 239 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Lipocine Inc. announced its financial results for the third quarter ended September 30, 2026, reporting a net loss of $0.7 million and total revenue of $2.3 million.
U.S. stocks fell Wednesday, led by industrials. Crude inventories dropped unexpectedly, while Penguin Solutions and Lipocine surged; Caribou Biosciences
Canada approves Lipocine’s TLANDO for adult males with testosterone deficiency. Partner Verity Pharma plans a launch by the end of 2026.
U.S. stocks fell Wednesday; Dow dropped 350 points. Energy rose, materials slid. Constellation beat estimates; oil gained while gold and silver fell.